NasdaqCM - Delayed Quote USD

Avenue Therapeutics, Inc. (ATXI)

0.2301

+0.0001

+(0.04%)

At close: 3:05:12 PM EDT

Avenue Therapeutics Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights

- Topline data in Phase 1b/2a clinical trial of AJ201 for spinal and bulbar muscular atrophy anticipated around year-end 2024MIAMI, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of neurologic diseases, today reported financial results and recent corporate highlights for the third quarter ended September 30, 2024. “We have gen

GlobeNewswire 5 months ago

ATXI
+0.04%

FBIO
-1.13%

FBIOP
Avenue Therapeutics to Participate in Maxim Group’s 2024 Healthcare Virtual Summit

MIAMI, Oct. 09, 2024 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of neurologic diseases, today announced that Alexandra MacLean, M.D., Chief Executive Officer of Avenue Therapeutics, will participate in a fireside chat at Maxim Group’s 2024 Healthcare Virtual Summit on Tuesday, October 15, 2024 at 1:30 PM ET. The fireside chat will be av

GlobeNewswire 6 months ago

ATXI
+0.04%

FBIO
-1.13%

FBIOP
Avenue Therapeutics to Participate in Upcoming Investor Conferences

MIAMI, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of neurologic diseases, today announced that Alexandra MacLean, M.D., Chief Executive Officer of Avenue Therapeutics, will participate in the following upcoming investor conferences: H.C. Wainwright 26th Annual Global Investment ConferenceDate: Monday, September 9, 2024Loc

GlobeNewswire 7 months ago

FBIO
-1.13%

FBIOP

ATXI
+0.04%
Fortress Biotech Reports Second Quarter 2024 Financial Results and Recent Corporate Highlights

PDUFA goal date of November 4, 2024 for DFD-29 for the treatment of inflammatory lesions and erythema of rosacea in adults FDA accepted Biologics License Application resubmission for cosibelimab to treat metastatic or locally advanced cutaneous squamous cell carcinoma; PDUFA goal date of December 28, 2024 MIAMI, Aug. 13, 2024 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on acquiring and advancing assets to enhance long-te

GlobeNewswire 8 months ago

FBIO
-1.13%

FBIOP

DERM
Avenue Therapeutics Reports Second Quarter 2024 Financial Results and Recent Corporate Highlights

- Last patient visit complete in Phase 1b/2a clinical trial of AJ201 for spinal and bulbar muscular atrophy; topline data anticipated in second half of 2024 – - Raised $4.4 million in gross proceeds from a May 2024 warrant exercise transaction - MIAMI, Aug. 09, 2024 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of neurologic diseases, toda

GlobeNewswire 8 months ago

FBIO
-1.13%

FBIOP

ATXI
+0.04%
Avenue Therapeutics to Present at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference

MIAMI, June 20, 2024 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of neurologic diseases, today announced that Alexandra MacLean, M.D., Chief Executive Officer of Avenue Therapeutics, will present at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference. The presentation will be available to registered attendees for on-dema

GlobeNewswire 10 months ago

FBIO
-1.13%

FBIOP

ATXI
+0.04%
Avenue Therapeutics Announces Last Patient Last Visit in Phase 1b/2a Clinical Trial of AJ201 for the Treatment of Spinal and Bulbar Muscular Atrophy (Kennedy's Disease)

Topline results of the Phase 1b/2a clinical trial anticipated mid-year 2024MIAMI, May 16, 2024 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of neurologic diseases, today announced the completion of the last patient’s final visit in the Company’s Phase 1b/2a clinical trial of AJ201 for the treatment of spinal and bulbar muscular atrophy (“

GlobeNewswire 11 months ago

ATXI
+0.04%

FBIO
-1.13%

FBIOP
Avenue Therapeutics Reports First Quarter 2024 Financial Results and Recent Corporate Highlights

– Raised a total of $9.4 million in gross proceeds from warrant exercise transactions since January 2024 – MIAMI, May 15, 2024 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of neurologic diseases, today reported financial results and recent corporate highlights for the first quarter ended March 31, 2024. “The first quarter was incredibly p

GlobeNewswire 11 months ago

FBIO
-1.13%

FBIOP

ATXI
+0.04%

Performance Overview

Return	ATXI	S&P 500 (^GSPC)
YTD	-88.50%	-4.72%
1-Year	-95.17%	+11.67%
3-Year	-99.94%	+35.63%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Avenue Therapeutics, Inc. (ATXI)

Avenue Therapeutics Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights

Avenue Therapeutics to Participate in Maxim Group’s 2024 Healthcare Virtual Summit

Avenue Therapeutics to Participate in Upcoming Investor Conferences

Fortress Biotech Reports Second Quarter 2024 Financial Results and Recent Corporate Highlights

Avenue Therapeutics Reports Second Quarter 2024 Financial Results and Recent Corporate Highlights

Avenue Therapeutics to Present at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference

Avenue Therapeutics Announces Last Patient Last Visit in Phase 1b/2a Clinical Trial of AJ201 for the Treatment of Spinal and Bulbar Muscular Atrophy (Kennedy's Disease)

Avenue Therapeutics Reports First Quarter 2024 Financial Results and Recent Corporate Highlights

Performance Overview